Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 15, 2012

Soricimed commences patient treatment in Phase I trial of SOR-C13

Soricimed Biopharma, a private clinical stage company, has started the treatment of their first patient in a Phase I clinical trial of anti-cancer agent SOR-C13, at the Juravinski Cancer Centre in Hamilton, Ontario, Canada.

Soricimed Biopharma, a private clinical stage company, has started the treatment of their first patient in a Phase I clinical trial of anti-cancer agent SOR-C13, at the Juravinski Cancer Centre in Hamilton, Ontario, Canada.

The multicentre, open-label study, which will take place at cancer centres in both Canada and the US, is designed to assess safety and tolerability of SOR-C13 in patients with advanced cancer tumours, with a focus on ovarian cancers.

"Unlike chemotherapy, the cancer treatment is highly targeted, affecting only cancer cells."

The dose escalation study will also assess pharmacokinetics, biomarkers and initial evidence for efficacy.

Soricimed Biopharma chairman and chief scientific officer Jack Stewart said that unlike chemotherapy, the company’s cancer treatment is highly targeted, affecting only cancer cells.

"Healthy cells are not affected. It’s also a biologic, meaning it’s derived from a naturally occurring peptide that when broken down produces amino acids that can be reused by the body," Stewart said.

"As a result, and this is key, there have been virtually no side effects demonstrated in our pre-clinical studies."

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The company expects to carry out Phase I trials till February 2013 and to release interim results later in 2012. If results are successful, further clinical trials will follow.

SOR-C13 works by inhibiting a non-voltage gated calcium channel found in epithelial cancers such as ovarian, breast and prostate.

Pre-clinical studies demonstrated that SOR-C13 induces apoptosis (cell death), inhibits cell proliferation and reduces tumour volume while minimising side effects associated with typical chemotherapy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU